Abstract
The ultimate goal in cancer therapy is achieving selective targeting of cancer cells. We report a novel delivery platform, based on nanoghosts (NGs) produced from the membranes of mesenchymal stem cells (MSCs). Encompassing MSC surface molecules, the MSC-NGs retained MSC-specific in vitro and in vivo tumor targeting capabilities and were cleared from blood-filtering organs. MSC-NGs were found to be biocompatible. Systemic administration of drug loaded MSC-NGs demonstrated 80% inhibition of human prostate cancer.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / pharmacokinetics
-
Cell Line, Tumor
-
Cell Membrane / chemistry*
-
Male
-
Mesenchymal Stem Cells / chemistry*
-
Mice
-
Mice, Inbred C57BL
-
Mice, Nude
-
Nanocapsules / administration & dosage
-
Nanocapsules / chemistry*
-
Nanocapsules / ultrastructure
-
Organ Specificity
-
Particle Size
-
Peptide Fragments / administration & dosage*
-
Peptide Fragments / pharmacokinetics*
-
Prostatic Neoplasms / drug therapy*
-
Prostatic Neoplasms / metabolism*
-
Receptors, TNF-Related Apoptosis-Inducing Ligand / administration & dosage*
-
Receptors, TNF-Related Apoptosis-Inducing Ligand / pharmacokinetics*
-
Tissue Distribution
-
Treatment Outcome
Substances
-
Antineoplastic Agents
-
Nanocapsules
-
Peptide Fragments
-
Receptors, TNF-Related Apoptosis-Inducing Ligand
-
soluble tumor necrosis factor-related apoptosis-inducing ligand (114-281), rat